Clinical Data QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS BioSpaceBiogen's Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis.NeuroscienceRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) BioSpace Biogen’s Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis. Neuroscience Read full story Post navigation Previous: Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beatNext: Viridian data lift prospects for thyroid eye disease drug Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
